Comparison · NCT04908189-b4350f64
Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16. Trial comparisons, record NCT04908189-b4350f64. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04908189-b4350f64
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.288 | 0.241 | 0.341 | wilson | |
| Risk in group 2 | 0.163 | 0.127 | 0.209 | wilson | |
| Risk difference, group 1 minus group 2 | 0.125 | 0.0595 | 0.189 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.76 | 1.3 | 2.4 | log | |
| Odds ratio, group 1 over group 2 | 2.07 | 1.41 | 3.06 | log | |
| Number needed to treat, for one more participant with the outcome on Deucravacitinib than on Placebo | 8 | 5.28 | 16.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Deucravacitinib | Deucravacitinib 6 mg daily | 90 | 312 | OG000 |
| Group 2 | Placebo | Placebo daily | 51 | 312 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16
- Description
The American College of Rheumatology (ACR) 50 is defined as 50% improvement over baseline in tender (68) and swollen (66) joint counts and a 50% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
- Time frame
- Week 16
- Population
- All randomized participants of deucravacitinib and placebo as pre-specified in protocol
Source ClinicalTrials.gov
Trial
- Title
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- NCT number
- NCT04908189
- Phases
- PHASE3
- Conditions
- Psoriatic Arthritis
- Interventions
- Deucravacitinib, Placebo, Apremilast
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2025-04-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04908189?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04908189-b4350f64